Nasdaq Approves Listing for Post-Merger Z Squared (ZSQR), Fulfilling Key Merger Condition

summarizeSummary

Coeptis Therapeutics announced Nasdaq's approval for the listing of the post-merger company's common stock under the ticker 'ZSQR', satisfying a key closing condition for its merger with Z Squared Inc.

check_boxKey Events

• Nasdaq Listing Approved

  Nasdaq has approved the listing of the post-merger company's common stock on the Nasdaq Global Market under the ticker symbol 'ZSQR'.

• Key Merger Condition Met

  This approval satisfies a crucial closing condition for the proposed merger between Coeptis Therapeutics and Z Squared Inc.

• Merger Expected in Q2 2026

  The transaction remains subject to satisfaction of any remaining customary closing conditions and is expected to close in Q2 2026.

• Company Transformation

  Upon closing, Coeptis will change its name to Z Squared Inc. and become a digital infrastructure company focused on Dogecoin and Litecoin mining.

auto_awesomeAnalysis

This 8-K officially confirms that Nasdaq has approved the listing of the post-merger entity's common stock under the new ticker 'ZSQR'. This approval is a critical closing condition for Coeptis Therapeutics' transformational merger with Z Squared Inc. For a company that previously disclosed a 'going concern' warning, satisfying such a key condition significantly de-risks the merger's completion, which is vital for its strategic shift from biopharmaceuticals to digital infrastructure and cryptocurrency mining. The market may have already reacted to the news reported yesterday, but this filing provides official confirmation.